US 11,987,796 B2
Interferon production using short RNA duplexes
Anna Marie Pyle, Guilford, CT (US); Andrew Kohlway, Santa Clara, CA (US); Dahai Luo, Proteos (SG); David Rawling, San Mateo, CA (US); and Akiko Iwasaki, Guilford, CT (US)
Assigned to Yale University, New Haven, CT (US)
Filed by YALE UNIVERSITY, New Haven, CT (US)
Filed on Aug. 25, 2020, as Appl. No. 17/002,252.
Application 17/002,252 is a division of application No. 14/776,463, granted, now 10,947,543, previously published as PCT/US2014/025578, filed on Mar. 13, 2014.
Claims priority of provisional application 61/779,514, filed on Mar. 13, 2013.
Prior Publication US 2021/0054380 A1, Feb. 25, 2021
Int. Cl. C12N 15/115 (2010.01); A61K 31/713 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01)
CPC C12N 15/115 (2013.01) [A61K 31/713 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 45/06 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01)] 13 Claims
 
1. A method for treating a disease or disorder in a subject, wherein the disease or disorder is selected from the group consisting of a bacterial infection, a viral infection, a parasitic infection, cancer, an autoimmune disease, an inflammatory disorder, and a respiratory disorder,
the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a ribonucleic acid (RNA) molecule,
wherein the RNA molecule is a single chain molecule and forms a hairpin structure consisting of a double-stranded section, a loop, and a blunt end,
wherein the number of base pairs in the double stranded section is 10, 11, 12, 13, 14, 15, 16, or 17,
wherein the molecule comprises a 5′-triphosphate or a 5′ diphosphate terminus group, and
wherein the administering induces type I interferon production in at least one cell of the subject.